For NSCLC patients without the T790M mutation, platinum-based chemotherapy is the recommended second-line therapy after progression on first- and second-generation EGFR-TKIs.(24) Nevertheless, a randomised phase 2 trial of 96 patients in Korea concluded that the outcomes of pemetrexed therapy for NSCLC patients with disease progression after first-line EGFR-TKI were not improved by adding cisplatin.(25) Thus, which chemotherapeutic regimen was optimal as the treatment standard was unclear. Here, EGFR is linked to non-small cell lung carcinoma.